Yuhan Corporation
000100.KS

$6.05 B
Marketcap
$81.95
Share price
Country
$3.28
Change (1 day)
$118.84
Year High
$40.69
Year Low

Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury; ETC products in the areas of cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems; anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics. It also offers OTC products, including vitamins and minerals, hepatopathy drugs and tonics, respiratory system drugs, alimentary system drugs, dermatology and analgesics drugs, and others; and household and healthcare products, such as bleaches, detergents, pesticides, and oral care products. In addition, the company engages in dental business and offers implants, dental equipment/consumable, and dental care products. Additionally, the company manufactures and sells medical supplies for livestock, aquatic animals, and household pets. Further, it provides contract manufacturing services. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

marketcap

P/E ratio for Yuhan Corporation (000100.KS)

P/E ratio as of 2023: 57.97

According to Yuhan Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 57.97. At the end of 2022 the company had a P/E ratio of 43.05.

P/E ratio history for Yuhan Corporation from 2007 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 57.97
2022 43.05
2021 41.51
2020 25.49
2019 70.26
2018 39.37
2017 20.31
2016 12.07
2015 21.16
2014 18.37
2013 21.56
2012 21.29
2011 13.69
2010 14.28
2009 14.86
2008 16.54
2007 19.89